华海药业：不向下修正“华海转债”转股价格

Core Viewpoint - Huahai Pharmaceutical (600521) announced that its board of directors decided not to exercise the right to lower the conversion price of "Huahai Convertible Bonds" for the current period and will not propose a downward adjustment in the next two months [1] Group 1 - The board resolution was made during the third temporary meeting of the ninth board of directors [1] - The period for potential downward adjustment of the conversion price is set from August 16, 2025, to October 15, 2025 [1] - Starting from October 16, 2025, the company will reassess whether to exercise the right to adjust the conversion price if the conditions are met [1]